These observations provide evidence that FOSL2 methylation state may be a useful biomarker for increasing risk of T2DM progression within the Uyghur population in Xinjiang and preventing a potential novel target for therapeutic development. This evidence concerns the gene FOSL2 and type 2 diabetes mellitus.